Mylan CEO Takes Center Stage To Address EpiPen Pricing Scandal

CEO Heather Bresch defended her company’s controversial decision to raise the price of the allergy medicine to $600 during the Forbes Healthcare Summit and even took questions from fellow pharma insiders like “Why did you ruin it?”

More from Drug Pricing

More from Scrip